Immunitybio is trading 10.3% down at $8.01 amid steep declines across the broader market and biotech, with no confirmed company announcement directly explaining the move.
- Supplied sector context shows XBI down 5.19%; market coverage also describes a broader biotech selloff.
- Third-quarter results were expected November 5, keeping sales uptake in focus, but available coverage does not link that anticipation to the decline.